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INTRODUCTION
The subject of this project was "colorectal cancer" and the focus area "inflammatory response in the development of colorectal cancer". Inflammatory bowel disease (IBD) is associated with the development of colorectal cancer; however, little is known about the mechanisms responsible for the progression of IBD to malignancy. The purpose of the work was to address the hypothesis that aberrant expression of the mucin 1 (MUC1) oncoprotein by chronic intestinal inflammation contributes to the development of colorectal cancers that are in turn dependent on MUC1 for the malignant phenotype. The scope of the research was to define the role of MUC1 in the growth and survival of human colon cancer cells growing in vitro and as tumor xenografts in nude mice and to develop a MUC1 + /IL-10 -/-model of colitis to determine whether MUC1 function affects the inflammatory response and colon tumorigenesis.
Background. MUC1 is a heterodimeric transmembrane protein that is activated in cytokine-mediated inflammatory responses (1) . MUC1 is aberrantly overexpressed in human colon cancers and is associated with invasion, metastases and a poor prognosis (2) (3) (4) (5) (6) (7) (8) . However, there is limited information regarding a functional role for MUC1 in colon cancer cells.
MUC1 consists of an extracellular N-terminal subunit (MUC1-N) with variable numbers of glycosylated tandem repeats and a C-terminal transmembrane subunit (MUC1-C) (1) . MUC1-N is shed from the epithelial cell surface, where it contributes to the intestinal mucosal barrier. In turn, MUC1-C signals growth and survival responses to the interior of cells constituting the epithelial layer (1) . The available evidence indicates that colon and other cancer cells have exploited MUC1-C-induced survival signals by aberrantly expressing this subunit. For example, MUC1-C contributes to activation of the WNT/β-catenin pathway, which is frequently activated in colon cancer (9) , by binding directly to and stabilizing β-catenin (10) . The MUC1-C cytoplasmic domain also interacts directly with TCF7L2/TCF4 and thereby promotes β-catenin/TCF4-mediated transcription of WNT target genes, such as cyclin D1 (11) .
Other studies have linked MUC1-C to the constitutive activation of NF-κB in human carcinomas (12) . In this context and like activated NF-κB, MUC1-C contributes to transformation and blocks apoptosis by a mechanism that involves in part upregulation of BCL-XL expression (13, 14) . These MUC1-C-induced responses are conferred by interaction of the MUC1-C cytoplasmic domain with the high-molecular weight IκB (IKK) complex (15) . In turn, MUC1-C promotes IKKβ activation, resulting in phosphorylation and degradation of IκBα (15) . Other work has demonstrated that MUC1-C interacts directly with NF-κB p65 and contributes to activation of NF-κB target genes, such as BCL-XL (12) . The interaction between MUC1-C and NF-κB has also been linked to the induction of ZEB1, a transcriptional repressor that drives EMT and cancer progression (16) .
The transforming growth factor β-activated kinase 1 (TAK1) is a proinflammatory effector that contributes to activation of the IKK complex and thereby the NF-κB pathway (17) . TAK1 is a key regulator of the innate immune response and inflammation (17, 18) . TAK1 has also been linked to colon cancer cell survival and the control of cell death (19) (20) (21) (22) . However, little is know about the control of TAK1 levels in inflammation and cancer. Our studies demonstrate that MUC1-C induces TAK1 expression in colon cancer cells. We show that (i) MUC1-C induces TAK1 expression by promoting NF-κB-mediated activation of the TAK1 promoter, and (ii) MUC1-C binds directly to TAK1 and confers the formation of a TAK1 complex with TRAF6, which in turn activates TAK1NF-κB signaling. In concert with these results, targeting MUC1-C with silencing or with an inhibitor suppresses the TAK1NF-κB pathway. Our studies extend to a MUC1 transgenic model of inflammatory bowel disease and colon tumorigenesis and provide further support for MUC1-C-mediated induction of TAK1NF-κB signaling.
BODY
Specific Aim 1: To determine if disrupting MUC1-C function affects the inflammatory response and colon tumorigenesis in a MUC1+/IL-10-/-mouse model of colitis.
Intestinal inflammation increases the risk of developing colon cancer, conceivably through recurrent cycles of damage and repair of the mucosa (23) . Aberrant expression of MUC1 protein has been linked to inflammatory bowel disease (24) (25) (26) ; however, to our knowledge, there is no available analysis of MUC1 and its relationship with inflammatory signals in models of colitis and colon tumorigenesis.
Therefore, to develop a mouse model of colitis and tumorigenesis, we first crossed MUC1 +/-(here MUC1 represents human MUC1) mice with IL-10 -/-mice (obtained from Jackson Laboratories) (Fig. 1A) . Genotyping was used for identification of F1 MUC1 +/-/IL-10 +/-mice (Fig. 1B) , which were then bred with IL-10 -/-mice (Fig. 1A) . Mice transgenic for human MUC1 (MUC1 +/-) that express MUC1 under control of the endogenous human MUC1 promoter exhibit a pattern of expression similar to that found in humans (27) . Immunoblot analysis of colon tissue from MUC1 +/-mice demonstrated increased MUC1-C levels as compared to that in wild-type mice ( Figs. 2A and B) . In addition, upregulation of MUC1-C in the MUC1 +/-mouse colon was associated with increases in TAK1 and phospho-NF-κB p65 ( Figs. 2A and B) . BCL-XL levels were also upregulated in colon tissue from the MUC1 +/-mouse ( Figs. 2A and B) . 
The MUC1
+/-mice did not develop colitis as evidenced by a normal colonic mucosa (data not shown). By contrast, IL-10 -/-mice develop colitis with epithelial hyperplasia and inflammatory infiltrates due to aberrant regulation of the innate immune response to intestinal flora (28) . To assess the effects of MUC1-C on TAK1 signaling in a model of colitis and tumorigenesis (29), we crossed MUC1 +/-mice with IL-10 -/-mice and then the F1 MUC1 +/-/IL-10 +/-mice were bred with IL-10 -/-mice. Analysis of colon tissue from IL-10 -/-mice demonstrated marked upregulation of endogenous mouse Muc1-C expression, but at levels somewhat lower than that found in the MUC1 +/-/IL-10 -/-mouse colon ( Fig. 3A and B) . We also found increases in TAK1, phospho-NF-κB p65 and BCL-XL that were more pronounced in the MUC1 +/-/IL-10 -/-mouse colon ( Fig. 3A and B) . The presence of colitis as assessed by the development of rectal prolapse supported increased inflammation of the bowel in MUC1 (Fig. 3C) . Moreover, and consistent with previous studies (29) , the MUC1 +/-/IL-10 -/-mice exhibited more severe colitis with dysplasia and progression to carcinomas (Fig. 3D) . Ongoing studies following completion of funding continue to monitor the MUC1
+/-and IL-10 -/-mice for rectal prolapse and for the development of colon tumors. At that time, additional tissues will be harvested for immunohistochemistry studies. Based on the findings to date, our hypothesis continues to be that MUC1 +/-/IL-10 -/-mice develop colitis at an earlier age than IL-10 -/-mice and also develop colon cancer at later stages of inflammation. Our plan will then be to determine whether treatment with GO-203 to disrupt MUC1 function attenuates colitis and colorectal tumor development. Having developed these models with support from the DOD, we will now continue these studies with other funding.
Specific Aim 2:
To assess the effects of inhibiting MUC1-C function on activation of the NF-κB, STAT3 and β-catenin pathways that have been linked to colitis and tumorigenesis.
MUC1 has been linked to three major signaling pathways (NF-κB p65, β-catenin and STAT3) associated with intestinal inflammation and colon tumorigenesis (1). Our studies, as described below, focused predominantly on the NF-κB p65 pathway based on the observation that MUC1-C is involved in the regulation of TAK1, which contributes to activation of the IKK complex and NF-κB p65 signaling. Our results also support a model in which MUC1 may contribute in part to inflammation and tumorigenesis through the Wnt/β-catenin, but not the STAT3, pathway.
Silencing MUC1-C decreases TAK1 signaling in colon cancer cells. SK-CO-1 colon cancer cells are dependent on TAK1 for survival (21) . MUC1-C was therefore stably silenced in SK-CO-1 cells to determine whether MUC1-C affects TAK1 signaling (Fig. 4A) . Notably, silencing MUC1-C in SK-CO-1/MUC1shRNA cells was associated with marked downregulation of TAK1 mRNA levels as compared to that in control SK-CO-1/CshRNA cells (Fig. 4B, left) . Silencing MUC1-C was also associated with decreases in TAK1 protein (Fig. 4B, right) . In addition, MUC1-C was necessary for activation of phospho-IKKβ and phospho-NF-κB p65 (Fig. 4C, left) . Intriguingly, treatment of SK-CO-1 cells with the NF-κB inhibitor BAY11-7085 (30) suppressed TAK1 mRNA levels (data not shown), indicating that MUC1-C may activate a TAK1-NF-κB autoinductive loop. In concert with these results, silencing MUC1-C decreased activation of a NF-κB p65-driven pGL4.32 promoter-Luc reporter (Fig. 4C, right) . To extend this analysis, MUC1-C was downregulated in SW620 colon cancer cells (Fig. 4D ). As found with SK-CO-1 cells, MUC1-C suppression in SW620 cells was associated with decreases in TAK1 expression (Fig. 4E , left and right). We also found that silencing of MUC1-C in SW620 cells results in suppression of NF-κB signaling (Fig. 4F, left and right) . These results indicate that MUC1-C contributes to activation of the inflammatory TAK1NF-κB pathway in colon cancer cells. 
. SK-CO-1 cells were infected with lentiviruses to stably express a control CshRNA or a MUC1shRNA. Lysates from the wild-type (WT) and transduced cells were immunoblotted with the indicated antibodies. B. TAK1 mRNA levels in the indicated SK-CO-1 cells were determined by qRT-PCR (left). The results are expressed as relative TAK1 mRNA levels (mean±SD of three determinations) as compared to that obtained for the SK-CO-1/CshRNA cells (left). Lysates were immunoblotted with the indicated antibodies (right). C. Lysates from SK-CO-1/CshRNA and SK-CO-1/MUC1shRNA cells were immunoblotted with the indicated antibodies (left). The indicated cells were transfected with pGL4.32-Luc for 48 h and then assayed for luciferase activity. The results are expressed as the relative luciferase activity (mean±SD of three determinations) compared to that obtained for the SK-CO-1/CshRNA cells (right). D. SW620 cells were infected with lentiviruses to stably express a control CshRNA or a MUC1shRNA. Lysates from the wild-type (WT) and transduced cells were immunoblotted with the indicated antibodies. E. TAK1 mRNA levels in the indicated SW620 cells were determined by qRT-PCR (left). The results are expressed as relative TAK1 mRNA levels (mean±SD of three determinations) as compared to that obtained for the SW620/CshRNA cells (left). Lysates were immunoblotted with the indicated antibodies (right). F. Lysates from the SW620/CshRNA and SW620/MUC1shRNA cells were immunoblotted with the indicated antibodies (left). The indicated cells were transfected with pGL4.32-Luc for 48 h and then assayed for luciferase activity. The results are expressed as the relative luciferase activity (mean±SD of three determinations) compared to that obtained for the SW620/CshRNA cells (right).
MUC1-C induces TAK1 expression. HCT116 colon cancer cells have low to undetectable levels of MUC1-C as compared to that in SK-CO-1 and SW620 cells. Accordingly, we stably overexpressed MUC1-C in these cells (Fig. 5A ) to further define the interaction between MUC1-C and TAK1. In concert with the finding that silencing MUC1-C downregulates TAK1 expression, we found that TAK1 mRNA levels are significantly increased in HCT116/MUC1-C, as compared to HCT116/vector, cells (Fig. 5B, left) . Expression of MUC1-C was also associated with increases in TAK1 protein (Fig. 5B, right) and phospho-NF-κB p65 (Fig. 5B, right) . Intriguingly, stable silencing of NF-κB p65 in HCT116/MUC1-C cells blocked MUC1-C-induced TAK1 expression (data not shown), providing further support for a potential auto-inductive loop involving MUC1-C, TAK1 and NF-κB. Similarly, in LoVo colon cancer cells transduced to stably overexpress MUC1-C (Fig. 5C ), we found increased activation of the TAK1 promoter (Fig. 5D, left) and upregulation of TAK1 mRNA levels (Fig.  5D, right) . Expression of MUC1-C was also associated with increases in TAK1 protein and in phospho-NF-κB p65 (Fig. 5E ). Consistent with activation of NF-κB p65, expression of MUC1-C in the LoVo cell model resulted in activation of the pGL4.32 promoter-Luc reporter (Fig. 5F ). These findings demonstrate that MUC1-C is sufficient for induction of TAK1 and the NF-κB pathway. 
. Lysates from HCT116 colon cancer cells transduced to stably express an empty vector or MUC1-C were immunoblotted with the indicated antibodies. B. TAK1 mRNA levels in the indicated HCT116 cells were determined by qRT-PCR (left). The results are expressed as relative TAK1 mRNA levels (mean±SD of three determinations) as compared to that obtained for the HCT116/vector cells (left). Lysates were immunoblotted with the indicated antibodies (right). C. Lysates from LoVo colon cancer cells transduced to stably express an empty vector or MUC1-C were immunoblotted with the indicated antibodies. D. The indicated LoVo cells were transfected with a TAK1 promoter-luciferase reporter (pTAK1-Luc) for 48 h and then assayed for luciferase activity. The results are expressed as the relative luciferase activity (mean±SD of three determinations) compared to that obtained for the LoVo/vector cells (left). qRT-PCR analysis of TAK1 mRNA in the indicated LoVo cells is expressed as relative levels (mean±SD of three determinations) as compared to that obtained for the LoVo/vector cells (right). E. Lysates from the LoVo/vector and LoVo/MUC1-C cells were immunoblotted with the indicated antibodies. F. The indicated LoVo cells were transfected with pGL4.32-Luc for 48 h and then assayed for luciferase activity. The results are expressed as the relative luciferase activity (mean±SD of three determinations) compared to that obtained for the LoVo cells.
MUC1-C promotes NF-κB p65 occupancy of the TAK1 promoter. Based on the above observations, we searched the human TAK1 (MAP3K7) promoter region using the annotated sequence available at the Ensembl genomic database (ENST00000369329; NCBI Reference Sequence: NG_011966.2) and found a potential NF-κB binding sequence at position -326 to -317 upstream to the transcription start site (Fig. 6A, upper panel) . To determine whether this putative NF-κB site contributes to activation of the TAK1 promoter, we compared activation of a wild-type (GGGACCAACC) and mutant (CTCACCAACC) TAK1 promoter-luciferase reporter (pTAK1-Luc) in SK-CO-1 cells. Mutation of the putative NF-κB site was associated with a significant decrease in TAK1 promoter activation (Fig. 6A, lower panel) . Based on these results, ChIP studies were performed which demonstrated that NF-κB p65 occupies the TAK1 promoter (Fig.  6B) . We also found that silencing MUC1-C in SK-CO-1 cells decreases NF-κB p65 occupancy (Fig. 6B) . ReChIP analysis further demonstrated that NF-κB p65 occupies the TAK1 promoter with MUC1-C (Fig. 6C) . In concert with these findings, activation of the pTAK1-Luc reporter in LoVo/MUC1-C cells was significantly attenuated by mutation of the NF-κB site (Fig. 6D) . Moreover, NF-κB p65 occupancy on the TAK1 promoter was increased in LoVo/MUC1-C, as compared to LoVo/vector, cells (Fig. 6E) . Re-ChIP studies using the LoVo cells further confirmed that NF-κB occupies the TAK1 promoter with MUC1-C (Fig. 6F) . These results collectively provided support for a model in which MUC1-C also promotes NF-κB-mediated activation of TAK1 expression. 
qPCR with pairs of primers for the NF-κB binding region (NBR). The results (mean±SD of three determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control. F. Soluble chromatin from the indicated LoVo cells was precipitated with anti-NF-κB p65. The precipitates were released, reimmunoprecipitated with anti-MUC1-C and then analyzed for TAK1 promoter sequences. The results (mean±SD of three determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control.
MUC1-C forms a complex with TAK1 and TRAF6. TAK1 phosphorylates IKKβ on Ser-181 and thereby activates the NF-κB pathway (31, 32) . The demonstration that MUC1-C associates with IKKβ (15) prompted studies to determine whether MUC1-C also forms a complex with TAK1. Indeed, coimmunoprecipitation (co-IP) experiments using lysates from SK-CO-1 cells showed that MUC1-C associates with TAK1 (Fig. 7A ). In concert with these co-IP results and the previous demonstration that MUC1-C interacts with the IKK complex (15), immunodepletion of MUC1-C from SK-CO-1 cell lysates was associated with decreases in TAK1, p-IKKβ and IKKβ (data not shown). As additional controls, MUC1-C/TAK1 complexes were also detectable when co-IP studies were performed on HCT116/MUC1-C, but not HCT116/vector, cell lysates (data not shown). These results collectively supported the association of MUC1-C and TAK1 in cells.
In vitro binding studies further demonstrated that the MUC1-C cytoplasmic domain (MUC1-CD; Fig. 7B ) interacts directly with GST-TAK1 (Fig. 7C) . To define the region of MUC1-CD that confers the interaction, we incubated GST-MUC1-CD deletion mutants with His-TAK1 (Fig. 7D) . The results showed that MUC1-CD(1-45), but not MUC1-CD(46-72), binds to TAK1 (Fig. 7D) . We also found that mutation of the MUC1-CD CQC motif to AQA abrogated binding to TAK1 (Fig. 7D) , indicating that the Cys residues are of importance for the interaction.
TNF receptor-associated factor 6 (TRAF6) is an E3 ubiquitin ligase that functions upstream to TAK1 and NF-κB activation (33) . Based on the known interaction between TAK1 and TRAF6, we asked if, like TAK1, MUC1-C also associates with TRAF6. Indeed, coimmunoprecipitation studies demonstrated that MUC1-C forms a complex with TRAF6 (Fig. 7E, left) . In addition, we found that the MUC1-C cytoplasmic domain (MUC1-CD) binds directly to GST-TRAF6 (Fig. 7E, right) . However, in contrast to TAK1, the interaction with TRAF6 was conferred by MUC1-CD(20-72) and not MUC1-CD(1-45) (Fig. 7F) . The lack of detectable binding of MUC1-CD(46-72) to TRAF6 (Fig. 7F) further supported involvement of a region spanning aa 45-46 and indicated that distinct regions of MUC1-CD bind to TAK1 and TRAF6. Moreover, and in contrast to TAK1, binding to TRAF6 was not affected by mutating MUC1-CD at CQC to AQA (Fig. 7F) . The observation that MUC1-CD interacts with both TAK1 and TRAF6 invoked the possibility that MUC1-CD might facilitate the formation of TAK1/TRAF6 complexes. Significantly, there was little if any association of His-TAK1 and GST-TRAF6 in the absence of MUC1-CD (Fig. 7G) . By contrast, binding of TAK1 and TRAF6 was clearly observed in the presence of MUC1-CD and this interaction was abrogated by mutation of the CQC motif to AQA (Fig.  7G ).
Figure 7. MUC1-C cytoplasmic domain binds directly to TAK1. A. Lysates from SK-CO-1 cells were precipitated with anti-MUC1-C or a control IgG. The precipitates were immunoblotted with the indicated antibodies. B. Schematic representation of MUC1-C (ED, extracellular domain; TM, transmembrane domain) and the amino acid (aa) sequence of the cytoplasmic domain (CD). Highlighted is the CQC motif that is necessary for MUC1-C homodimerization and has been mutated to AQA in MUC1-CD. C. GST or GST-TAK1 was incubated with purified MUC1-CD. The adsorbates were immunoblotted with anti-MUC1-CD. Input of the GST proteins was assessed by Coomassie blue staining. D. GST, GST-MUC1-CD (full-length; 1-72) or the indicated GST-MUC1-CD mutants were incubated with His-TAK1. The adsorbates were immunoblotted with anti-TAK1. Input of the GST proteins was assessed by Coomassie blue staining. E. Lysates from SK-CO-1 cells were precipitated with anti-MUC1-C or a control IgG. The precipitates were immunoblotted with the indicated antibodies (left). GST or GST-TRAF6 was incubated with purified MUC1-CD. The adsorbates were immunoblotted with anti-MUC1-CD (right). Input of the GST proteins was assessed by Coomassie blue staining (right). F. GST, GST-MUC1-CD(1-72) or the indicated GST-MUC1-CD mutants were incubated with His-TRAF6. The adsorbates were immunoblotted with anti-TRAF6. Input of the GST proteins was assessed by Coomassie blue staining. G. His-TAK1 was incubated with GST or GST-TRAF6 in the presence of MUC1-CD or MUC1-CD(AQA). Adsorbates and input proteins were immunoblotted with the indicated antibodies. Input of the GST-TRAF6 and GST proteins was assessed by Coomassie blue staining.
TRAF6 bridges the RAS and NF-κB pathways in lung cancer cells (34) ; however, little is known about involvement of TRAF6 in colon cancer cells. Of interest in this regard, silencing MUC1-C in SK-CO-1 and SW620 cells was associated with downregulation of TRAF6 mRNA and protein (Figs. 8A and 8B , left and right). Consistent with these results, expression of MUC1-C in HCT116 cells resulted in upregulation of TRAF6 mRNA and protein levels (Fig. 8C, left and right) . Moreover, we found that MUC1-C induces TRAF6 expression in LoVo cells (Fig. 8D, left and right) , indicating that MUC1-C is sufficient to drive the upregulation of both TAK1 and TRAF6.
Figure 8. MUC1-C upregulates TRAF6 expression. A and B. TRAF6 mRNA levels in the indicated SK-CO-1 (A) and SW620 (B) cells were determined by qRT-PCR (left). The results are expressed as relative TRAF6 mRNA levels (mean±SD of three determinations) as compared to that obtained for the CshRNA cells (left). Lysates were immunoblotted with the indicated antibodies (right). C and D. TRAF6 mRNA levels in the indicated HCT116 (C) and LoVo (D) cells were determined by qRT-PCR (left). The results are expressed as relative TRAF6 mRNA levels (mean±SD of three determinations) as compared to that obtained for the vector cells (left). Lysates were immunoblotted with the indicated antibodies (right).

Specific Aim 3:
To define the mechanisms associated with inhibiting MUC1-C that block growth and survival of human colon cancer cells growing in vitro and as xenografts in nude mice.
Targeting the MUC1-C CQC motif blocks TAK1NF-κB signaling. The findings that MUC1-C induces TAK1 expression and binds directly to TAK1 prompted studies with the cell-penetrating peptide GO-203 that targets the MUC1-C CQC motif and blocks MUC1-C function (35) (Fig. 9A, upper panel) . As a control, we used another cell-penetrating peptide, designated CP-2, in which the critical Cys residues for binding to endogenous MUC1-C were mutated to Ala (Fig. 9A, upper panel) . Treatment of SK-CO-1 cells with GO-203, but not CP-2, was associated with suppression of TAK1 expression and decreases in NF-κB p65 phosphorylation (Fig. 9A, lower panels) . We also found that treatment with GO-203 downregulates expression of the NF-κB target gene, BCL-XL (Fig. 9A, lower panels) . These effects of GO-203 were conferred, at least in part, by inhibition of NF-κB-mediated transactivation as determined by studies with the pGL4.32 promoter-Luc reporter (Fig. 9B) . GO-203 also blocked the interaction between TAK1 and TRAF6 in SK-CO-1 cells (Fig. 9C) . TAK1 contributes to the activation of both (i) NF-κB and (ii) β-catenin/TCF4 signaling in colon cancer cells (21) . Accordingly, we asked if targeting MUC1-C and thereby downregulating TAK1 expression also affects the β-catenin/TCF4 pathway. Indeed, silencing MUC1-C in SK-CO-1 and SW620 cells was associated with decreases in activation of the β-catenin/TCF4-driven TOP-Flash promoter-reporter (Figs. 10A and 10B ). Silencing MUC1-C was also associated with decreases in AXIN2, the product of a β-catenin/TCF4-dependent target gene (Figs. 10C and 10D ), indicating that MUC1-C contributes to activation of the TAK1NF-κB and β-catenin/TCF4 pathways. Nonetheless, the novelty of a MUC1-C-dependent TAK1 and NF-κB auto-inductive loop that confers upregulation of BCL-XL prompted our focus on that pathway. 
levels in the indicated SK-CO-1 (C) and SW620 (D) cells were determined by qRT-PCR (left). The results are expressed as relative TAK1 mRNA levels (mean±SD of three determinations) as compared to that obtained for the CshRNA cells (left). Lysates from the indicated SK-CO-1 (C) and SW620 (D) cells were immunoblotted with anti-AXIN2 and anti-β-actin (right).
To further assess the effects of targeting MUC1-C, MUC1-positive SK-CO-1 (Fig. 11A) , (Fig. 11B) and COLO-320 (Fig. 11C ) colorectal cancer cells were left untreated (Control) and treated with 2.5 µM GO-203 or CP-2 for the indicated times. Treatment with GO-203 was associated with inhibition of growth and loss of survival (late apoptosis/necrosis) (Figs. 11A-C) . By contrast, the control CP-2 peptide had little if any effect (Figs. 11A-C) . In addition, treatment of MUC1-negative HCT116 colon cancer cells with GO-203 was ineffective in inhibiting growth (Fig. 11D ). These findings demonstrate that human colorectal cancer cells that express MUC1 are dependent on MUC1-C for their growth and survival. Previous studies demonstrated that MEK inhibitors are highly effective against KRAS mutant cancers when combined with agents that target BCL-XL (36) . Therefore, based on the finding that GO-203 decreases BCL-XL, we treated SK-CO-1 cells with GO-203 in combination with the MEK inhibitor AS703026. Inhibitory effects of the GO-203+AS703026 combination on SK-CO-1 colony formation were more pronounced than with either agent alone (Fig. 12A, upper panel) . Moreover, isobologram analysis of the combination showed marked synergy with a combination index of less than 0.1 (Fig. 12A , lower panels; Table 1 ). Similar results were obtained when GO-203 was combined with the MEK inhibitor GSK1120212 (Fig. 12B , upper and lower panels; Table 1 ). These findings with SK-CO-1 cells were confirmed when SW620 cells were treated with the combination of GO-203 and MEK inhibitors (Figs. 12C and D; Table 1 ), indicating that GO-203 is synergistic with different MEK inhibitors. Table 1 . ) in the flanks of nude mice. Groups of 8 mice each were treated intraperitoneally (ip) with PBS (Control), 18 mg/kg GO-203, or 18 mg/kg CP-3 each day for 28 days (Fig. 13A) . Compared to the control group, growth of the COLO-205 tumors was inhibited in the GO-203-treated mice (Fig.  13A) . Moreover, these tumors regressed completely by the end of treatment (day 28) and there was no evidence for regrowth by day 180 (Fig. 13A) . In contrast to the anti-tumor activity of GO-203, treatment with CP-3 had no effect on COLO-205 tumor growth (Fig. 13A) . Importantly, GO-203 was not associated with loss of body weight or other apparent toxicities. Studies were also performed on established subcutaneous SK-CO-1 tumor xenosgrafts (~90 mm 3 ) to explore other GO-203 dose-schedules (Fig. 13B) . Groups of 8 mice each were treated with PBS (Control), 6 mg/kg GO-203 each day for 5 days intravenously (iv), or 3 mg/kg GO-203 each day for 5 days iv each week for two weeks. The results demonstrate that, as compared to the control group, growth of tumors in the mice treated with GO-203 was inhibited with both dose-schedules (Fig. 13B) . These findings indicate that GO-203 is effective in inhibiting growth and survival of MUC1-positive colorectal cancer cells in mouse xenograft models. The findings also support a GO-203 dose-response effect with regression of tumors at higher doses (18 mg/kg) administered for longer periods (28 days). 
d. The multiple effect isobologram analyses on day 4 are shown for the ED50 (X), ED75 (+) and ED90 (o) values (lower left panel). The combination index (CI) is indicated with the arrow (lower right panel). CI values are included in
KEY RESEARCH ACCOMPLISHMENTS
The key research accomplishments emanating from this research are that: (1) the MUC1-C oncoprotein induces expression of TAK1, an essential effector of inflammation, in human colon cancer cells; (2) MUC1-C also induces TAK1 and thereby the proinflammatory NF-κB pathway in a transgenic mouse model of MUC1-driven colitis and colon tumorigenesis; (3) MUC1-C promotes NF-κB-mediated activation of TAK1 transcription and, in a positive regulatory loop, MUC1-C contributes to TAK1-induced NF-κB signaling (Fig. 14) ; (4) MUC1-C binds directly to TAK1 and confers the association of TAK1 with TRAF6, which is necessary for TAK1-mediated activation (Fig. 14) ; (5) targeting MUC1-C with the GO-203 inhibitor suppresses the TAK1NF-κB pathway and thereby downregulates BCL-XL; and (6) GO-203 is synergistic with MEK inhibitors in the treatment of colon cancer cells; and (7) targeting MUC1-C with GO-203 inhibits growth of MUC1-positive colon cancer cells growing in vitro and as xenografts in mice. These findings collectively support the importance of MUC1-C in activation of the TAK1NF-κB pathway in promoting intestinal inflammation and colon cancer progression. 
REPORTABLE OUTCOMES
There are no reportable outcomes to date from this research funding. A manuscript describing these results is now under review for publication.
